Phase 3Recruiting

(Peak) A Phase 3 Randomized Trial of Bezuclastinib (CGT9486)+Sunitinib vs. Sunitinib in Participants With Gastrointestinal Stromal Tumors

A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors

Sponsor
Cogent Biosciences, Inc. (Industry)
Enrollment
482 planned
Conditions
Advanced Gastrointestinal Stromal Tumors; Metastatic Cancer
Interventions
Bezuclastinib; Bezuclastinib; Sunitinib; Sunitinib; Midazolam; Bezuclastinib; Sunitinib; Bezuclastinib; Sunitinib
Ages
adults, older adults
Registry
NCT05208047

Full record on ClinicalTrials.gov

From the registry

This is a Phase 3, open-label, international, multicenter study of bezuclastinib in combination with sunitinib. This is a multi-part study that will enroll approximately 482 participants. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of bezuclastinib to be used in subsequent parts in approximately 20 participants who have received at least one prior line of therapy for Gastrointestinal Stromal Tumors (GIST) and 2) evaluating the potential for drug-drug interactions between bezuclastinib and sunitinib in approximately 18 participants who have received at least two prior tyrosine kinase inhibitors (TKIs) for GISTs. The second part of the study will enroll approximately 388 participants who are intolerant to, or who failed prior treatment with imatinib only and will compare the efficacy of bezuclastinib plus sunitinib to sunitinib alone with participants being randomized in a 1:1 manner. This study also contains two substudies: 1) a drug-drug interactions (DDI) substudy will investigate the potential for bezuclastinib to be a Cytochrome P450…

Primary outcomes

  • Part 1a - pharmacokinetics - Cmax
  • Part 1a - pharmacokinetics - AUC
  • Part 1b - pharmacokinetics - Cmax
  • Part 1b - pharmacokinetics - AUC

History

  1. Study completion expected

  2. Last registry update

  3. Primary completion

  4. Started

  5. Registered